dwinnex.com

Actinium Pharmaceuticals, Inc. [ATNM] took an upward turn with a change of -2.52%, trading at the price of $0.24 during the trading session on Thursday. The price movement in correlation with percentage of the mentioned increase can allow a valuable insight to investors. During the last trading session 2.23 million shares changed hands being bought and sold, while Actinium Pharmaceuticals, Inc. shares have an average trading volume of 1.62M shares for that time period. ATNM monthly volatility recorded 9.43%, in the meanwhile having share price volatility for the week set at 8.61%. PS value for ATNM stocks is with PB recorded at 4.87.

Actinium Pharmaceuticals, Inc. [NYSE:ATNM]: Analyst Rating and Earnings

Stock market traders frequently keep their eyes on what Wall Street experts as it relates to a potential investment. For Actinium Pharmaceuticals, Inc. [ATNM], the most recent analyst consensus recommendation available since its latest financial results for the quarter ending in December. On average, stock market experts give ATNM an Outperform rating. Its stock price has been found in the range of 0.25 to 0.87. This is compared to its latest closing price of $0.25.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Actinium Pharmaceuticals, Inc. [ATNM] is sitting at 2.00. This is compared to 1 month ago, when its average rating was 1.80.

Keep your eyes peeled for the soon-to-be-published financial results of this company, which are expected to be made public on Thu 8 Aug (In 55 Days).

Fundamental Analysis of Actinium Pharmaceuticals, Inc. [ATNM]

Turning to investigate this organization’s capital structure, Actinium Pharmaceuticals, Inc. [ATNM] has generated a Total Debt to Total Equity ratio of 2.98. Similarly, its Total Debt to Total Capital is 2.89, while its Total Debt to Total Assets stands at 1.76. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 0.15, and its Long-Term Debt to Total Capital is 0.15. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.

What about valuation? This company’s Enterprise Value to EBITDA is -1.21. Total Debt to Enterprise Value stands at 0.01. Actinium Pharmaceuticals, Inc. [ATNM] has a Price to Book Ratio of 5.08.

This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.36 and its Current Ratio is 2.36. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Actinium Pharmaceuticals, Inc. [ATNM] has 168.08M shares outstanding, amounting to a total market cap of $40.96M. Its stock price has been found in the range of 0.25 to 0.87. At its current price, it has moved down by -71.83% from its 52-week high, and it has moved down -0.53% from its 52-week low.

This stock’s Beta value is currently 2.02, which indicates that it is 8.61% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 30.24. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Actinium Pharmaceuticals, Inc. [ATNM] a Reliable Buy?

Actinium Pharmaceuticals, Inc. [ATNM] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.